General
Preferred name
DIQUAFOSOL
Synonyms
Diquas ()
DIQUAFOSOL TETRASODIUM ()
INS-365 ()
Diquafosol tetrasodium salt ()
Diquafosol sodium ()
DE-089 ()
INS365 ()
INS 365 ()
KPY-998 ()
Diquafosol (sodium salt) ()
P&D ID
PD050276
CAS
59985-21-6
211427-08-6
Tags
drug candidate
natural product
drug
available
Approved by
PMDA
First approval
2010
Drug indication
Dry eye disease
Drug Status
experimental
investigational
approved
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The USAN specifies the tetrasodium salt formulation. (GtoPdb)
Compound Sets
15
Cayman Chemical Bioactives
33971
ChEMBL Drugs
CHEMBL221326
CHEMBL1767408
Concise Guide to Pharmacology 2017/18
1736
Concise Guide to Pharmacology 2019/20
1736
Concise Guide to Pharmacology 2021/22
1736
Concise Guide to Pharmacology 2023/24
1736
Drug Repurposing Hub
DrugBank
DB15919
DrugCentral
4900
DrugCentral Approved Drugs
4900
DrugMAP
DM64QG9
EU-OPENSCREEN Bioactive Compound Library
EOS100741
Guide to Pharmacology
1736
Natural product-based probes and drugs
Selleckchem Bioactive Compound Library
diquafosol-tetrasodium
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
789.99
Hydrogen Bond Acceptors
21
Hydrogen Bond Donors
10
Rotatable Bonds
14
Ring Count
4
Aromatic Ring Count
2
cLogP
-4.19
TPSA
404.45
Fraction CSP3
0.56
Chiral centers
12.0
Largest ring
6.0
QED
0.08
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
purinergic receptor activator
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Dry Eye Syndrome
Target
P2 Receptor
Source data